Quick Facts About Micard

• Hypertension (High Blood Pressure): May be used to support the reduction of high blood pressure, which may help lower the risk of subsequent cardiovascular events.
• Cardiovascular Risk Reduction: May be used to reduce the potential for major cardiovascular events, such as heart attack or stroke, in individuals aged 55 and older who have a high-risk profile and are unable to use ACE inhibitors.

---

What Micard treats: main uses and benefits

Micard (telmisartan) is a prescription medication utilized in therapeutic domains related to the cardiovascular system. It is indicated for the treatment of hypertension (high blood pressure). Supporting blood pressure control is part of a comprehensive cardiovascular risk management plan and may assist in reducing the risk of serious cardiovascular events, including both fatal and nonfatal stroke and myocardial infarction (heart attack).

Micard may also be used in adults aged 55 and older to support the reduction of cardiovascular risk. This indication is specifically for patients at a heightened risk of developing major cardiovascular events, such as those with a documented history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or certain high-risk types of diabetes. Treatment in this domain is typically used for patients who cannot tolerate therapy with an Angiotensin-Converting Enzyme (ACE) inhibitor.

Before initiating treatment, patients should consult with a healthcare provider to discuss the appropriate regimen and potential benefits.

Micard (telmisartan) eligibility is strictly defined by regulatory criteria, encompassing age, reproductive status, organ function, and specific comorbidities.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in patients with known hypersensitivity to telmisartan. It is also contraindicated during the second and third trimesters of pregnancy and must be discontinued immediately if pregnancy is detected. Absolute contraindications extend to patients with severe hepatic impairment or biliary obstructive disorders.

Age and Condition-Specific Restrictions

The safety and efficacy of Micard have not been established for use in children and adolescents under 18 years of age. For nursing mothers, a regulatory decision is required to discontinue nursing or discontinue the drug.

Use is contraindicated when co-administered with Aliskiren in patients with diabetes mellitus. Additionally, use is restricted in patients with mild to moderate hepatic impairment and those with volume or salt depletion (the condition must be corrected prior to therapy).

Interactions with other medicines and products

The regulatory information for Nicardipine hydrochloride documents specific interaction patterns concerning metabolism, pharmacodynamic effects, and food consumption.

---

Drug-Drug Interactions (Pharmacokinetic)

The medicine acts as a documented inhibitor of the CYP3A4 enzyme, which can significantly alter the exposure of certain co-administered medicines. Specifically, Nicardipine increases the plasma levels of both Cyclosporine and Tacrolimus. Conversely, co-administration with Cimetidine is officially stated to increase the plasma concentration of Nicardipine.

Pharmacodynamic Effects and Restrictions

A risk of severe hypotension has been reported when Nicardipine, as a calcium channel blocker, is combined with a beta-blocker during Fentanyl Anesthesia. Official labeling also documents a procedural constraint when transitioning between formulations: the first oral dose must be administered one hour prior to the discontinuation of the intravenous infusion.

Food and Population Notes

Co-administration of the oral formulation with grapefruit juice significantly increases the drug's exposure, leading to higher AUC and peak plasma concentrations. Furthermore, regulatory restrictions note that the extended-release capsules must not be co-administered with high-fat foods or high-fat meals. Official labeling also notes that patients with impaired renal or hepatic function exhibit significantly reduced systemic clearance and a higher Area Under the Curve (AUC) for the drug.

How Micard Works

Nicardipine is a small molecule that influences the body’s mechanisms for regulating arterial tension. Its action is based purely on molecular intervention in cell signaling.

---

Inhibiting Calcium Influx in Arterial Muscle

This mechanism details the molecule’s direct action on its molecular target: the L-type voltage-gated calcium channels ( L-VGCCs) embedded in the arterial smooth muscle cell membranes. Nicardipine acts as an antagonist, physically blocking these channels to prevent the influx of extracellular calcium ions ( Ca^2+). This suppression of calcium influx halts the excitation-contraction coupling process, which is a key molecular cascade for muscle fibers to contract.

---

Modulating Systemic Vascular Resistance

The collective cellular effect of smooth muscle relaxation translates into the physiological consequence of peripheral arterial vasodilation (widening of the resistance arteries). This widening directly decreases the Systemic Vascular Resistance (SVR), which is the total resistance against which the heart must pump blood (afterload). By modulating this key resistance component, the mechanism results in a change in blood flow dynamics.

---

Constraints of the Mechanistic Cascade

While active in inducing vasodilation, the mechanism is subject to the body’s internal regulatory feedback systems. Specifically, the rapid drop in arterial pressure caused by the mechanism can immediately trigger the baroreceptor reflex, a compensatory response where the autonomic nervous system attempts to normalize pressure by increasing the heart rate (reflex tachycardia). This reflex is an intrinsic physiological constraint on the drug's action.

Micard is administered through two distinct routes: as an oral capsule for ongoing therapeutic management and as a continuous intravenous (IV) infusion for acute needs. The oral formulation dictates the frequency of use, with immediate-release capsules typically taken three times daily (TID) and sustained-release capsules generally taken twice daily (BID).

For chronic oral use, the typical starting dose for the immediate-release capsule is 20 mg TID. Dosage increases are made gradually, with a minimum interval of at least three days between adjustments to ensure stable drug concentrations. Oral capsules may be taken without regard to meals, though high-fat meals can affect absorption of the immediate-release form.

The injectable form is reserved for acute care and must be administered by slow continuous IV infusion in controlled hospital environments with continuous monitoring. The initial infusion rate is typically 5 mg/ hour, which can be carefully titrated up to a maximum rate of 15 mg/ hour. The solution requires dilution using compatible IV fluids prior to administration.

Dose modification is utilized for certain patient groups. For instance, a lower starting dose is advised for patients with hepatic impairment. When transitioning from the IV infusion to the oral TID regimen, the first oral dose must be administered one hour prior to discontinuing the intravenous therapy.

Research evidence / Overview of Studies for Micard

The research foundation for Micard (Nicardipine) primarily consists of controlled clinical trials and comparative studies examining cardiovascular function and outcomes related to systemic or functional imbalance, such as those in blood pressure and angina symptoms. Findings describe group patterns, not personal outcomes, and evidence highlights what is known — and what is still uncertain.

---

Evidence for use in Chronic Stable Angina Pectoris (Oral Capsule)

The oral capsule was studied for use in exploring patterns related to chronic stable angina. Research explored functional assessments, such as treadmill exercise duration. Findings describe patterns observed in the studies, where the duration of exercise and the time until the onset of angina were observed to be greater in those receiving the study drug compared to those receiving the inactive substance. Furthermore, studies describe patterns where lower measurements of anginal attack frequency and need for nitroglycerin were observed.

Evidence for use in Essential Hypertension (Oral Capsule)

The oral formulation was evaluated in controlled trials for chronic high blood pressure. Research highlights changes measured during the study period, primarily reporting measurements showing lower systolic and diastolic blood pressure in the observed populations. Some studies monitored responses over periods of up to one year, with data showing patterns where the blood pressure measurements were observed to remain lower over these intermediate-term intervals.

---

Evidence in Specific Patient Groups and Clinical Subsets

Clinical trial evidence has included older adults with hypertension, and findings suggest that the patterns of blood pressure reduction appear to be similar to those observed in younger adult populations. However, data for certain groups remain insufficient. For instance, the safety and effectiveness have not been established in pediatric patients (under 18 years old). The medicine was observed in the acute care setting for severe hypertension in pregnancy; however, long-term effects are not yet fully established for the infant.

Key Studies & References

1. Nicardipine Hydrochloride Capsules 20 mg and 30 mg Rx only - DailyMed

Common questions about Micard (FAQ)

Q: Is Micard a long-term treatment, or is it intended for temporary use?

A: Official product information indicates that the oral form of Telmisartan is used for the sustained, long-term management of high blood pressure. Nicardipine is also prescribed for the long-term management of chronic stable angina. Regulatory documents indicate these medications are generally prescribed for the sustained, long-term management of their conditions, rather than temporary use.

Q: Is there a timeframe for how long common side effects when starting Micard might last?

A: For Telmisartan, common side effects like dizziness and headache often appear when starting therapy and may be observed to lessen over time. For Nicardipine, official documents note that a dose-dependent side effect like peripheral edema (swelling) may typically appear within the first few weeks of starting treatment.

Q: What types of allergic reactions are listed for Micard?

A: Serious allergic reactions reported for Telmisartan include angioedema (swelling of the face, neck, and mouth), anaphylactic reaction, and generalized hypersensitivity. These reactions are officially documented for the medication.

Q: Can Micard be safely combined with other types of blood pressure medications?

A: Telmisartan is sometimes indicated for use in combination with other antihypertensive agents to manage high blood pressure. However, official information notes that the co-administration of Telmisartan with certain classes of medicines, such as ACE inhibitors, is associated with an increased risk of side effects like low blood pressure and kidney issues.

Q: What does the research evidence indicate about Micard's ability to prevent cardiovascular events?

A: According to official product labeling, Telmisartan's primary function is to lower high blood pressure. Official labeling states that reducing blood pressure is associated with a reduction in the risk of serious cardiovascular events, including strokes and heart attacks.

Q: What are the common signs of low blood pressure that may occur while taking Micard?

A: Symptoms associated with low blood pressure (hypotension) that may occur include dizziness, lightheadedness, and fainting. These symptoms are typically observed when starting treatment or following a dosage change.

Q: Is it typical to experience dizziness or lightheadedness when starting Micard treatment?

A: Yes, official product information lists dizziness and headache as common side effects for Telmisartan. These effects are often noted when first beginning the medication.

Q: What are the different strengths Micard is available in?

A: Telmisartan oral tablets are available in 20 mg, 40 mg, and 80 mg strengths. Nicardipine capsules are available in several immediate-release and sustained-release strengths, such as 20 mg and 30 mg for the immediate-release form.

Q: Is Micard generally considered safe for elderly patients (over 65)?

A: Official research indicates that the blood pressure-lowering effect of Telmisartan is generally not influenced by age. While efficacy patterns are similar in the elderly, caution is generally recommended when initiating treatment, often starting at the low end of the adult dosing range.

Q: How does Micard affect the heart's workload?

A: The medicine's core action is to promote vasodilation (artery widening). This decreases the Systemic Vascular Resistance (SVR), or the total resistance against which the heart must pump blood (known as afterload). Reducing this resistance generally results in a lighter workload for the heart.

Q: What is the difference between using Micard for hypertension and for cardiovascular risk reduction?

A: Official labeling states that treating high blood pressure (hypertension) is the primary goal of Telmisartan. By successfully lowering blood pressure, the medication delivers an associated benefit of reducing the overall risk of cardiovascular events, such as strokes and heart attacks.

Q: Is back pain a frequent side effect mentioned in official documentation for Micard?

A: Yes, official documentation for Telmisartan lists back pain as a common adverse event.

Q: Does Micard cause the same kind of dry cough associated with ACE inhibitors?

A: Coughing is listed as an adverse event for Telmisartan. Although coughing is listed as an adverse event for Telmisartan, it is generally recognized that this class of medicines (ARBs) has a different side effect profile than ACE inhibitors.

Q: How quickly can a person expect to see the full blood pressure-lowering effect of Micard?

A: The onset of the blood pressure-lowering activity for Telmisartan is noticeable within hours after the first dose. Official product information indicates that the maximal blood pressure reduction is typically reached by about four weeks after beginning treatment.

Q: What risk is associated with Micard regarding potassium levels in the blood?

A: Official documentation for Telmisartan notes that it may cause high potassium levels in the blood, a condition called hyperkalemia. Official guidance indicates that monitoring of potassium levels is often necessary during treatment.

Q: Is there a recommended time of day for taking Micard?

A: While the medicine can be taken with or without food, official guidance for Telmisartan states that it should be taken at the same time each day. Taking the medication at the same time each day helps maintain consistent drug levels.

Q: Can Micard be taken at the same time as common over-the-counter pain relievers?

A: The regulatory information on Telmisartan notes a potential interaction with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen. This combination may increase the risk of kidney function issues and could reduce the medicine's ability to lower blood pressure.

Q: Are there specific concerns about Micard interacting with lithium?

A: Yes, official product information on Telmisartan states that it may increase the blood levels of lithium, which can raise the risk of lithium toxicity. The monitoring of serum lithium levels is advised if the two medicines are taken together.

Q: Does Micard interact with herbal supplements or vitamins?

A: Regulatory guidance advises individuals to inform their healthcare providers about all other medications, including vitamins and herbal products. This disclosure is necessary to help the provider assess potential risks from interactions.

Q: What is the general advice about alcohol consumption while on Micard?

A: Official information indicates that alcohol may have an additive effect in lowering blood pressure. This effect can potentially increase the risk of symptoms like dizziness, lightheadedness, and fainting while taking the medication.

Q: Does the efficacy of Micard differ between men and women?

A: According to the official product information for Telmisartan, the antihypertensive effect is not found to be influenced by patient gender.

Q: Can Micard cause increased urination (micturition frequency)?

A: Yes, changes in urinary frequency, or micturition frequency, are listed as a rare side effect in the official documentation for Telmisartan.

Q: What are the inactive ingredients found in Micard tablets?

A: The inactive ingredients vary by form and strength. For Nicardipine capsules, inactive ingredients include magnesium stearate and pregelatinized starch, with other colorants and components depending on the specific strength.

Q: What is the relationship between Micard and reducing the risk of stroke?

A: Official product information for Telmisartan indicates that the medicine is used to lower high blood pressure. Reducing blood pressure is a key factor in reducing the risk of cardiovascular events, including strokes.

Q: Is it safe to use potassium-containing salt substitutes while taking Micard?

A: Official information for Telmisartan advises against the use of potassium-containing salt substitutes or supplements. This is due to the potential for the medicine to increase blood potassium levels, known as hyperkalemia.

Q: What happens if Micard is stopped abruptly?

A: Official labeling for Telmisartan indicates that upon discontinuation, blood pressure gradually returns to pre-treatment levels over a period of several days to one week.

Q: What are the common initial signs that Micard is starting to work?

A: Official documentation indicates the earliest effect is a measurable reduction in blood pressure, noticeable within hours after the first dose.

Q: Are there specific instructions for what to do if vomiting or severe diarrhea occurs while taking Micard?

A: Official warnings note that severe vomiting or diarrhea can cause fluid or salt depletion, which may lead to symptomatic low blood pressure. Correction of the depleted fluid or salt is necessary to avoid symptomatic low blood pressure.

Q: Does official documentation mention any impact of Micard on gout or uric acid levels?

A: Yes, official documentation for Telmisartan lists gout as an uncommon side effect.

Q: What is the typical terminal elimination half-life of the active ingredient in Micard?

A: The terminal elimination half-life is approximately 24 hours for Telmisartan and 8.6 hours for Nicardipine.

Micardis (Telmisartan) tablets are officially required to be stored under controlled conditions to protect their stability, primarily due to their hygroscopic nature, meaning they are sensitive to moisture.

Official Storage and Handling

• Temperature: Store at Controlled Room Temperature, 20^circ to 25 C (68^circ to 77 F), with permitted excursions up to 30 C (86 F).
• Container and Protection: The product must be stored in the original container and protected from moisture. Tablets must not be removed from the sealed blister until immediately before administration.
• Child Safety: Keep the medication out of the sight and reach of children.

Disposal Requirements

Disposal of any unused product or waste material must be done in accordance with local requirements. The official label generally advises against disposing of the medicine via wastewater or household rubbish, unless specific household disposal instructions are provided by the regulator.